Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer
Figure 3
Anti-tumor to TA-CIN/GPI-0100 vaccination in the TC-1 lung metastasis model.
A. Schematic illustration of the experimental protocol. Briefly, 5∼8 weeks old female C57BL/6 mice (10 mice/group) were injected with 5×104 TC-1 cells intravenously on day 0. On day 3, the mice were vaccinated s.c. with either 6.25 µg/mouse of TA-CIN, or formulated with 50 µg of GPI-0100, or formulated with 50 µg of GPI-0100 in 50.7 mg/mL of mannitol and frozen/thawed once. The mice were boosted twice with the same regimen with 1-week interval. On day 21, the mice were sacrificed to harvest lungs and spleens. B. Summary of the number of TC-1 metastasis nodules (and photographs of lungs are presented in S5A Fig.). C. Summary of the weight of the lungs of the mice.